TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DERMATOLOGIC ENDPOINTS FROM 2 PHASE 3 STUDIES

Disclosure of Interests: Joseph F. Merola Consultant for: Biogen IDEC, Abbvie, Amgen, Eli Lilly and Company, Novartis, Pfizer, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, Merck, and GSK, Kim Papp Grant/research support from: AbbVie, Akros, Allergan, Amgen, Anacor, Arcutis, Astellas, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb.

DOI: 10.1136/annrheumdis-2019-eular.798

Meaning		GPA: Results on MC, N=100				GPA: Results on MC, N=100			
	Toleration Fac 120 N=102	Toleration Fac 120 N=102	Absent Adequacy Fac 120 N=102	PRO Fac 120 N=102	Toleration Fac 120 N=102	Toleration Fac 120 N=102	PRO Fac 120 N=102	PRO Fac 120 N=102	
1.5 mean (SD) percentage change from baseline in PMSD score ^{a,b}									
1	-0.02	-0.39	-0.57	-0.62	-0.39	-0.39	-0.39	-0.39	
2	-0.11 (0.44)	-0.13 (0.44)	-0.13 (0.44)	-0.13 (0.44)	-0.13 (0.44)	-0.13 (0.44)	-0.13 (0.44)	-0.13 (0.44)	
3	-0.16 (0.44)	-0.16 (0.44)	-0.16 (0.44)	-0.16 (0.44)	-0.16 (0.44)	-0.16 (0.44)	-0.16 (0.44)	-0.16 (0.44)	
4	-0.24 (0.44)	-0.24 (0.44)	-0.24 (0.44)	-0.24 (0.44)	-0.24 (0.44)	-0.24 (0.44)	-0.24 (0.44)	-0.24 (0.44)	
5	-0.31 (0.44)	-0.31 (0.44)	-0.31 (0.44)	-0.31 (0.44)	-0.31 (0.44)	-0.31 (0.44)	-0.31 (0.44)	-0.31 (0.44)	
6	-0.37 (0.44)	-0.37 (0.44)	-0.37 (0.44)	-0.37 (0.44)	-0.37 (0.44)	-0.37 (0.44)	-0.37 (0.44)	-0.37 (0.44)	
7	-0.43 (0.44)	-0.43 (0.44)	-0.43 (0.44)	-0.43 (0.44)	-0.43 (0.44)	-0.43 (0.44)	-0.43 (0.44)	-0.43 (0.44)	
8	-0.49 (0.44)	-0.49 (0.44)	-0.49 (0.44)	-0.49 (0.44)	-0.49 (0.44)	-0.49 (0.44)	-0.49 (0.44)	-0.49 (0.44)	
9	-0.55 (0.44)	-0.55 (0.44)	-0.55 (0.44)	-0.55 (0.44)	-0.55 (0.44)	-0.55 (0.44)	-0.55 (0.44)	-0.55 (0.44)	
10	-0.61 (0.44)	-0.61 (0.44)	-0.61 (0.44)	-0.61 (0.44)	-0.61 (0.44)	-0.61 (0.44)	-0.61 (0.44)	-0.61 (0.44)	
11	-0.67 (0.44)	-0.67 (0.44)	-0.67 (0.44)	-0.67 (0.44)	-0.67 (0.44)	-0.67 (0.44)	-0.67 (0.44)	-0.67 (0.44)	
12	-0.73 (0.44)	-0.73 (0.44)	-0.73 (0.44)	-0.73 (0.44)	-0.73 (0.44)	-0.73 (0.44)	-0.73 (0.44)	-0.73 (0.44)	
Number of respondents achieving PMSD score ^a available at visit (% with baseline PMSD = 0) ^{a,b}									
1	13 (6.0)	13 (6.0)	13 (6.0)	13 (6.0)	13 (6.0)	13 (6.0)	13 (6.0)	13 (6.0)	
2	23 (10.9)	23 (10.9)	23 (10.9)	23 (10.9)	23 (10.9)	23 (10.9)	23 (10.9)	23 (10.9)	
3	33 (15.8)	33 (15.8)	33 (15.8)	33 (15.8)	33 (15.8)	33 (15.8)	33 (15.8)	33 (15.8)	
4	43 (20.5)	43 (20.5)	43 (20.5)	43 (20.5)	43 (20.5)	43 (20.5)	43 (20.5)	43 (20.5)	
5	53 (25.2)	53 (25.2)	53 (25.2)	53 (25.2)	53 (25.2)	53 (25.2)	53 (25.2)	53 (25.2)	
6	63 (30.1)	63 (30.1)	63 (30.1)	63 (30.1)	63 (30.1)	63 (30.1)	63 (30.1)	63 (30.1)	
7	73 (35.0)	73 (35.0)	73 (35.0)	73 (35.0)	73 (35.0)	73 (35.0)	73 (35.0)	73 (35.0)	
8	83 (39.9)	83 (39.9)	83 (39.9)	83 (39.9)	83 (39.9)	83 (39.9)	83 (39.9)	83 (39.9)	
9	93 (44.8)	93 (44.8)	93 (44.8)	93 (44.8)	93 (44.8)	93 (44.8)	93 (44.8)	93 (44.8)	
10	103 (49.7)	103 (49.7)	103 (49.7)	103 (49.7)	103 (49.7)	103 (49.7)	103 (49.7)	103 (49.7)	
11	113 (54.6)	113 (54.6)	113 (54.6)	113 (54.6)	113 (54.6)	113 (54.6)	113 (54.6)	113 (54.6)	
12	123 (59.5)	123 (59.5)	123 (59.5)	123 (59.5)	123 (59.5)	123 (59.5)	123 (59.5)	123 (59.5)	
Number of respondents achieving PMSD score ^a available at visit (% with baseline PMSD = 0) ^{a,b}									
1	823 (39.0)	823 (39.0)	823 (39.0)	823 (39.0)	823 (39.0)	823 (39.0)	823 (39.0)	823 (39.0)	
2	923 (43.9)	923 (43.9)	923 (43.9)	923 (43.9)	923 (43.9)	923 (43.9)	923 (43.9)	923 (43.9)	
3	1023 (48.8)	1023 (48.8)	1023 (48.8)	1023 (48.8)	1023 (48.8)	1023 (48.8)	1023 (48.8)	1023 (48.8)	
4	1123 (53.7)	1123 (53.7)	1123 (53.7)	1123 (53.7)	1123 (53.7)	1123 (53.7)	1123 (53.7)	1123 (53.7)	
5	1223 (58.6)	1223 (58.6)	1223 (58.6)	1223 (58.6)	1223 (58.6)	1223 (58.6)	1223 (58.6)	1223 (58.6)	
6	1323 (63.5)	1323 (63.							